Metabiomics’ Exec: Test Can Be a Cheaper and More Accurate Alternative to Colonoscopies

Metabiomics is developing a noninvasive screening test for colon polyps in colorectal cancer based on human microbiome markers. In an interview with OneMedRadio, Gregory Kuehn, Vice President of Business Development at Metabiomics, explained that the preliminary data showed “sensitivity in excess of 97%” and specificity “as high as 93%.” Metabiomics will present at the upcoming OneMedForumNY 2013 on June 27th.

Read more »

Atossa Genetics’ Portfolio Can Detect Breast Cancer. But Can These Products Eradicate It?

Atossa Genetics believes it can prevent breast cancer by 2020 — and in the meantime, capture a unique market opportunity — with their novel cellular and molecular diagnostic risk assessment products for early detection. Yet in a burgeoning diagnostics space, and rapid advancement in cancer therapeutics, will this company find a niche?

Read more »

White Paper Explores the Amarantus Bioscience Alzheimer’s Disease Diagnostic

Amarantus Bioscience has posted a White Paper exploring the company’s LymPro Alzheimer’s Disease diagnostic, prepared by a member of the company’s Board of Advisors. The Paper discusses the increasing prevalence of Alzheimer’s disease, the clinical and economic advantages of early detection, and why the LymPro Test is poised to potentially become the market leading diagnostic product in the Alzheimer’s space.

Read more »

Caprion’s Proteomic Biomarkers — Diverse Clientele Leads to In-House Pipeline

Montreal-based Caprion has established itself as a leader in the proteomic biomarker discovery field, using its proteomics discovery platform CellCarta® to develop pharmacodynamic biomarkers, disease markers and predictive biomarkers. OneMedRadio spoke with Caprion President and CEO Martin Leblanc about industry trends concerning increased risk factors, securing intellectual property and developing an in vitro diagnostics platform.

Read more »

OneMedRadio: Vijay Aggarwal Part II

In Part II of our interview with Vijay Aggarwal, Managing Partner of the Channel Group, we explore trends in the space, reimbursement issues, and the state of equity financing. Dr. Aggarwal also discusses changing investment strategy with regards to evaluating risk factors, a more sophisticated level of proof, and an evolving emphasis on the achieving and maintaining revenue during early financing rounds.

Read more »

So What Happens if Medicare Stops Paying Its Bills?

The “elephant in the room” is the shifting, uncertain complexity of our regulatory and legislative environment. Exactly to that point, on Wednesday, March 27th Dr. Scott Gottlieb, a Forbes contributor focusing on policy, regulation, and public health posted an article entitled “Medicare Has Stopped Paying Bills For Medical Diagnostic Tests. Patients Will Feel”, which instantly caused a collective shiver among some diagnostics-focused investors and advisory groups. Experts shared their views on the Forbes article and its implications with us.

Read more »

OneMedRadio: Vijay Aggarwal Discusses Diagnostics Trends in 2013 (Part I)

As we approach mid-year, many questions raised in the past year surrounding the state of healthcare company growth development have […]

Read more »

RELEASE: Glysure Earns ISO 13485 Certification

GlySure Limited, developer of in-hospital continuous blood glucose monitoring systems, today announced that it has achieved ISO 13485 certification, the global standard for the requirements of a quality management system for the design, manufacture and distribution of medical devices. By establishing a quality management system that meets international regulatory and customer requirements, GlySure has set the foundation for its European clinical trials.

Read more »

2013, A Year for Point-of-Care Diagnostics Growth

Response Biomedical Corp. (RBM.TO)(RPBIF) is bringing in 2013 with a bang announcing their 2nd US distribution deal since the 1st week in January. Earlier in the month Response Biomedical entered a distribution agreement with US hospital supplier Laboratory Supply Company Inc. (Labsco) to distribute its cardiovascular portfolio of RAMP® products to small hospitals. By the end of January Response Biomedical announced their 2nd US distribution agreement with Fishers Healthcare for their RAMP® Flu A + B tests and RAMP® RSV test on the RAMP® 200.

Read more »

Cognoptix: Eye Scanning Test for Early Detection of Alzheimer’s Disease Represents Significant Market Opportunity

Cognoptix, presenting at the 6th Annaul OneMedForum, January 7-9 in San Francisco, is a privately held medical device company creating and developing a simple, innovative non-invasive eye scanning test for the early detection and diagnosis of Alzheimer’s Disease.

Read more »